Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.

Inclusion Criteria: 1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year. 2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma. 3. Patients who are at least 18 years of age. 4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf. Exclusion Criteria: 1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation. 2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment. 3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson. 4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)